Floatz logo

Tislelizumab

Brentuximab Vedotin

Children's Cancer Group, Chinamonoclonal_antibodyPhase 2/3Active
CCC
55/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
81/ 100

Competitive context

8 Active assets in the Brentuximab Vedotin cohort.

Asset / SponsorPhaseRating
Brentuximab Vedotin
Assistance Publique - Hôpitaux de Paris
Phase 3B
Inno-206
The First Affiliated Hospital with Nanjing Medical University
Phase 2/3B
PREDNISONE TABLETS
The First Affiliated Hospital with Nanjing Medical University
Phase 2/3B
Cyclophosphamide
The First Affiliated Hospital with Nanjing Medical University
Phase 2/3B
ETOPOSIDE
Children's Cancer Group, China
Phase 2/3CCC
DACARBAZINE
Children's Cancer Group, China
Phase 2/3CCC
Bedamustine
Children's Cancer Group, China
Phase 2/3CCC
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
The First Affiliated Hospital with Nanjing Medical University
Phase 2CCC

Same molecule, other indications

Tislelizumab is also rated in:

non-small cell lung carcinomaDormant
BB
Indicative ·
69 / 100
View asset →
Hepatic Metastasis of Pancreatic CancerDormant
BB
Indicative ·
69 / 100
View asset →
Primary Peritoneal Cavity CancerDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →